Literature DB >> 3259246

Antibodies reactive with human immunodeficiency virus gag-coded antigens (gag reactive only) are a major cause of enzyme-linked immunosorbent assay reactivity in a blood donor population.

D E Tribe1, D L Reed, P Lindell, W R Kenealy, B Q Ferguson, R Cybulski, D Winslow, D M Waselefsky, S R Petteway.   

Abstract

Normal blood donors were examined for human immunodeficiency virus (HIV)-reactive antibodies with both virus- and Escherichia coli-expressed env- and gag-coded antigens. The frequency of samples from normal (low-risk) donors that were repeatedly reactive with an HIV enzyme-linked immunosorbent assay blood screening test (Du Pont Co.) was 0.6%. Two classes of HIV serological reactivity were identified: a minor env-reactive class (0.03 to 0.06% of donors) and the predominant env-nonreactive gag-reactive class (gag reactive only [GRO]) (0.4 to 0.5% of donors). Assignment of env reactivity was made by a synthetic (recombinant) env enzyme-linked immunosorbent assay and virus immunoblot. Most GRO sera reacted with p15/p17 bands on HIV immunoblot. Antibody specificity in GRO sera was confirmed by competition-binding studies with viral gag and E. coli-expressed p55gag. This study provides independent verification that gag-specific antibodies are present in many env-nonreactive sera. More serological and virological studies of individuals with this antibody pattern should be pursued to determine the origin of these gag-reactive antibodies.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3259246      PMCID: PMC266397          DOI: 10.1128/jcm.26.4.641-647.1988

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  31 in total

1.  Complete nucleotide sequence of the AIDS virus, HTLV-III.

Authors:  L Ratner; W Haseltine; R Patarca; K J Livak; B Starcich; S F Josephs; E R Doran; J A Rafalski; E A Whitehorn; K Baumeister
Journal:  Nature       Date:  1985 Jan 24-30       Impact factor: 49.962

2.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

3.  Enzyme-linked immunoelectrotransfer blot techniques (EITB) for studying the specificities of antigens and antibodies separated by gel electrophoresis.

Authors:  V C Tsang; J M Peralta; A R Simons
Journal:  Methods Enzymol       Date:  1983       Impact factor: 1.600

4.  Human T-lymphotropic retrovirus type III/lymphadenopathy-associated virus antibody. Association with hemophiliacs' immune status and blood component usage.

Authors:  J Jason; J S McDougal; R C Holman; S F Stein; D N Lawrence; J K Nicholson; G Dixon; M Doxey; B L Evatt
Journal:  JAMA       Date:  1985-06-21       Impact factor: 56.272

5.  AIDS serology testing in low- and high-risk groups.

Authors:  J R Carlson; M L Bryant; S H Hinrichs; J K Yamamoto; N B Levy; J Yee; J Higgins; A M Levine; P Holland; M B Gardner
Journal:  JAMA       Date:  1985-06-21       Impact factor: 56.272

6.  Antibodies reactive with human T-lymphotropic retroviruses (HTLV-III) in the serum of patients with AIDS.

Authors:  M G Sarngadharan; M Popovic; L Bruch; J Schüpbach; R C Gallo
Journal:  Science       Date:  1984-05-04       Impact factor: 47.728

7.  Monoclonal antibody to human T-cell leukemia virus p19 defines polypeptide antigen in human choriocarcinoma cells and syncytiotrophoblasts of first-trimester placentas.

Authors:  J Suni; A Närvänen; T Wahlström; P Lehtovirta; A Vaheri
Journal:  Int J Cancer       Date:  1984-03-15       Impact factor: 7.396

8.  Analysis of human serum antibodies to human immunodeficiency virus (HIV) using recombinant ENV and GAG antigens.

Authors:  W Kenealy; D Reed; R Cybulski; D Tribe; P Taylor; C Stevens; T Matthews; S Petteway
Journal:  AIDS Res Hum Retroviruses       Date:  1987       Impact factor: 2.205

9.  Detection of IgG antibodies to lymphadenopathy-associated virus in patients with AIDS or lymphadenopathy syndrome.

Authors:  F Brun-Vezinet; C Rouzioux; F Barre-Sinoussi; D Klatzmann; A G Saimot; W Rozenbaum; D Christol; J C Gluckmann; L Montagnier; J C Chermann
Journal:  Lancet       Date:  1984-06-09       Impact factor: 79.321

10.  Human placental syncytiotrophoblastic Mr 75,000 polypeptide defined by antibodies to a synthetic peptide based on a cloned human endogenous retroviral DNA sequence.

Authors:  J Suni; A Närvänen; T Wahlström; M Aho; R Pakkanen; A Vaheri; T Copeland; M Cohen; S Oroszlan
Journal:  Proc Natl Acad Sci U S A       Date:  1984-10       Impact factor: 11.205

View more
  7 in total

1.  Reactivity patterns and infection status of serum samples with indeterminate Western immunoblot tests for antibody to human immunodeficiency virus type 1.

Authors:  E Ramirez; P Uribe; D Escanilla; G Sanchez; R T Espejo
Journal:  J Clin Microbiol       Date:  1992-04       Impact factor: 5.948

2.  Reliable confirmation of antibodies to human immunodeficiency virus type 1 (HIV-1) with an enzyme-linked immunoassay using recombinant antigens derived from the HIV-1 gag, pol, and env genes.

Authors:  V L Ng; C S Chiang; C Debouck; M S McGrath; T H Grove; J Mills
Journal:  J Clin Microbiol       Date:  1989-05       Impact factor: 5.948

3.  Cleavage of procaryotically expressed human immunodeficiency virus fusion proteins by factor Xa and application in western blot (immunoblot) assays.

Authors:  S Ellinger; R Glockshuber; G Jahn; A Plückthun
Journal:  J Clin Microbiol       Date:  1989-05       Impact factor: 5.948

4.  Characterization of antibodies reacting with HIV gag proteins occasionally found in the serum of non-infected subjects.

Authors:  P Bürgisser; P C Frei
Journal:  Clin Exp Immunol       Date:  1991-08       Impact factor: 4.330

5.  Agreement study between two laboratories of immunofluorescence as a confirmatory test for human immunodeficiency virus type 1 antibody screening.

Authors:  J Mahony; K Rosenthal; M Chernesky; S Castriciano; E Scheid; M Blajchman; D Harnish
Journal:  J Clin Microbiol       Date:  1989-06       Impact factor: 5.948

6.  Anti-human immunodeficiency virus type 1 antibodies of noninfected subjects are not related to autoantibodies occurring in systemic diseases.

Authors:  R Kämmerer; P Bürgisser; P C Frei
Journal:  Clin Diagn Lab Immunol       Date:  1995-07

7.  An Accurate Confirmation of Human Immunodeficiency Virus Type 1 (HIV-1) and 2 (HIV-2) Infections with a Dot blot assay Using Recombinant p24, gp41, gp120 and gp36 Antigens.

Authors:  Mehrdad Ravanshad; Farzaneh Sabahi; Fereidoun Mahboudi; Mohammad Hassan Roostaee; Ramin Sarami Forooshani; Anoshiravan Kazemnejad
Journal:  Int J Med Sci       Date:  2004-10-15       Impact factor: 3.738

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.